Ph PharmaEssentia Corp. announced that it submitted the new drug registration of BESREMi 500mcg/ml solution for injection in prefilled syringe (Ropeginterferon alfa-2b) for PV to the Drug Office, Hong Kong Department of Health.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
285.5 TWD | -1.04% | 0.00% | -17.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.49% | 2.9B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 6446 Stock
- News PharmaEssentia Corporation
- PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong